WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
XDC Academy
Antibody–Radionuclide Conjugates (ARCs) and WuXi XDC’s capabilities in ARCs
Antibody–Radionuclide Conjugates (ARCs) are a rapidly growing field. Four ARCs drugs in the world have been approved for marketing, and at least 100 ARCs are in active preclinical and clinical development, as of January 6, 2025. The past several years have witnessed significant advancements in ARCs. This slides deck provides a brief introduction and competitive landscape of ARCs as well as WuXi XDC’s combabilities in ARCs and other bioconjugates.
Discuss This Content
To discuss this content, please complete the form on the following page to connect with our experts.
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?